Genus plc to Announce Preliminary 2020 Year End Financial and Business Results on September 8, 2020
04 September 2020 - 10:30PM
Business Wire
World leader in animal genetics to webcast
financial and operational highlights at 7:01 AM BST, 1:01 AM
EDT
Genus plc (LSE: GNS), a world leading animal genetics company
producing superior breeding livestock through genetic improvement,
today announced that it will release its preliminary financial
results for the full year ended June 30, 2020, and provide a
business update on recent corporate developments in its worldwide
porcine and bovine genetics businesses, on Tuesday, September 8,
2020.
Webcast Results Presentation A pre-recorded briefing by
management to discuss the preliminary results for the year ended
June 30, 2020 will be held via a video webcast facility and will be
accessible at the following link beginning at 7:01 AM BST, 1:01 AM
EDT on September 8th:
https://webcasting.buchanan.uk.com/broadcast/5f28011c65023062edd7e24a.
An archived recording of the webcast will also be available on
the Investors section of the Company’s website.
About Genus Genus advances animal breeding and genetic
improvement by applying biotechnology and sells added value
products for livestock farming and food producers. Its technology
is applicable across livestock species and is currently
commercialised by Genus in the dairy, beef and pork food production
sectors.
Genus's worldwide sales are made in over 75 countries under the
trademarks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and
comprise semen, embryos and breeding animals with superior genetics
to those animals currently in farms. Genus's customers' animals
produce offspring with greater production efficiency and quality,
and our customers use them to supply the global dairy and meat
supply chains.
Genus’s competitive edge comes from the ownership and control of
proprietary lines of breeding animals, the biotechnology used to
improve them and its global supply chain, technical service and
sales and distribution network.
Headquartered in Basingstoke, United Kingdom, Genus companies
operate in over 25 countries on six continents, with research
laboratories located in Madison, Wisconsin, USA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200904005300/en/
Company Contacts: Genus plc Stephen Wilson, Chief
Executive Officer Alison Henriksen, Chief Financial Officer Tel:
01256 345970 Investor Relations and Media Contacts:
United Kingdom Buchanan Charles Ryland / Chris Lane /
Charlotte Slater Tel: 0207 466 5000 United States
LaVoieHealthScience Donna LaVoie / Sharon Choe / Paul Sagan
Tel: 617-374-8800 psagan@lavoiehealthscience.com
Genus (LSE:GNS)
Historical Stock Chart
From Apr 2024 to May 2024
Genus (LSE:GNS)
Historical Stock Chart
From May 2023 to May 2024